D (difficile)
This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| D (difficile) | |
|---|---|
.png) | |
| Name | D (difficile) |
| Domain | Bacteria |
| Phylum | Firmicutes |
| Classis | Clostridia |
| Ordo | Clostridiales |
| Familia | Peptostreptococcaceae |
| Genus | Clostridioides |
| Species | difficile |
D (difficile) is an anaerobic, spore-forming, gram-positive bacterium associated with healthcare-associated and community-acquired diarrheal disease. First characterized in the 1970s during investigations of antibiotic-associated colitis, it has since been linked to outbreaks and rising morbidity and mortality in diverse settings. International public health agencies, clinical microbiology laboratories, and infection control programs monitor its incidence and evolving strain diversity.
Taxonomy and Nomenclature
The organism was reclassified from the genus Clostridium to Clostridioides following molecular phylogenetic studies that compared 16S rRNA and whole-genome sequences with taxa including Bacillus anthracis, Listeria monocytogenes, Mycobacterium tuberculosis, Escherichia coli, and Staphylococcus aureus. Historical literature often refers to earlier descriptions by researchers associated with institutions such as Centers for Disease Control and Prevention and World Health Organization laboratories. Taxonomic debates involve comparisons with related genera represented in collections at the American Type Culture Collection, the European Molecular Biology Laboratory, and university herbaria at Harvard University, University of Oxford, and Stanford University.
Microbiology and Characteristics
The bacterium is a spore-forming obligate anaerobe with features described using methods developed at Pasteur Institute, Max Planck Society, and clinical labs at Mayo Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital. Phenotypic assays reference protocols from Clinical and Laboratory Standards Institute and genetic markers characterized by projects like Human Microbiome Project and sequencing efforts at Broad Institute. Virulence is driven by toxin genes first mapped in comparative genomics with strains archived at Institut Pasteur and sequenced in collaborations with Wellcome Trust Sanger Institute and National Institutes of Health. The organism’s spores resist disinfectants and persist on surfaces studied in environmental microbiology programs at University of California, Berkeley, Imperial College London, and ETH Zurich.
Epidemiology and Transmission
Epidemiologic patterns have been documented in surveillance systems run by Public Health England, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and national ministries such as Ministry of Health (France), Robert Koch Institute, and Health Canada. Outbreak investigations have implicated long-term care facilities like those overseen by NHS England and acute-care hospitals affiliated with Cleveland Clinic and Kaiser Permanente. Transmission studies reference travel- and community-associated cases reported in cohort studies from University of Toronto, Karolinska Institutet, and University of Sydney. Risk factors include exposures documented in antimicrobial stewardship programs at Johns Hopkins Hospital and guidelines from Infectious Diseases Society of America and Society for Healthcare Epidemiology of America.
Clinical Manifestations and Diagnosis
Clinical presentations range from mild diarrhea to fulminant pseudomembranous colitis; severe disease management involves multidisciplinary teams from centers like Mount Sinai Hospital, Guy’s and St Thomas’ NHS Foundation Trust, and Royal Melbourne Hospital. Diagnostic algorithms use nucleic acid amplification tests standardized by Food and Drug Administration clearances and laboratory practices taught at Mayo Clinic Laboratories, Quest Diagnostics, and academic centers such as University College London. Endoscopic and histopathologic findings are interpreted in consultation with departments at Johns Hopkins Hospital, Massachusetts General Hospital, and Cleveland Clinic Foundation. Biomarkers and severity scores have been validated in multicenter trials coordinated through networks like National Institutes of Health and European Society of Clinical Microbiology and Infectious Diseases.
Treatment and Management
Antimicrobial therapy recommendations draw on randomized trials compared across centers including Oxford University Hospitals, Vanderbilt University Medical Center, Mount Sinai Hospital, and pharmaceutical trials registered with agencies like European Medicines Agency and Food and Drug Administration. First-line agents historically included metronidazole and vancomycin; fidaxomicin and fecal microbiota transplantation protocols have been developed and evaluated at Mayo Clinic, University of Minnesota, and Massachusetts General Hospital. Surgical management for toxic megacolon involves colorectal teams at Cleveland Clinic and Royal Free Hospital. Antimicrobial stewardship initiatives from Infectious Diseases Society of America and Centers for Disease Control and Prevention inform protocols used at Kaiser Permanente and Johns Hopkins Hospital.
Prevention and Infection Control
Infection control guidance is issued by World Health Organization, Centers for Disease Control and Prevention, Public Health England, and specialty bodies including Society for Healthcare Epidemiology of America and Infectious Diseases Society of America. Environmental cleaning standards and sporicidal disinfectants are evaluated by laboratories at National Institute for Public Health and the Environment (Netherlands), National Institutes of Health, and industrial partners collaborating with 3M and Ecolab. Hand hygiene campaigns modeled after initiatives at World Health Organization and Centers for Disease Control and Prevention are implemented in hospitals such as Great Ormond Street Hospital and Royal Infirmary of Edinburgh. Vaccines and passive immunotherapies under investigation involve industry and academic consortia including GlaxoSmithKline, Pfizer, Sanofi, and research teams at University of Oxford and Harvard Medical School.
Research and Emerging Issues
Current research topics include genomic epidemiology using platforms like Nextstrain, antimicrobial resistance mechanisms compared with pathogens studied at Wellcome Trust Sanger Institute and Broad Institute, and microbiome therapeutics developed at MIT, Harvard Medical School, and Stanford University School of Medicine. Clinical trials of vaccines and monoclonal antibodies are registered with European Medicines Agency and Food and Drug Administration and conducted at centers including Mayo Clinic and University of California, San Francisco. Global surveillance studies coordinated by World Health Organization and European Centre for Disease Prevention and Control monitor hypervirulent lineages identified in international collections at Institut Pasteur and National Institutes of Health. Emerging concerns intersect with antimicrobial stewardship programs at Centers for Disease Control and Prevention and One Health initiatives involving Food and Agriculture Organization, World Organisation for Animal Health, and agricultural research institutes such as USDA.